ClinicalTrials.gg
Active, not recruitingNCT02285192Updated Dec 30, 2025

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

A Phase 1 interventional study of 18F-Fluorodeoxyglucose (18F-FDG) and PET/CT imaging in Cervical Cancer and Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Uterine Cervical Neoplasms by Memorial Sloan Kettering Cancer Center — 1 open to participants now, 3 under way, none of them phase 3. Uterine Cervical Neoplasms · Memorial Sloan Kettering Cancer Center.

Started
2014
the only one that year
Phase 1
2 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Uterine Cervical Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the only one that started in 2014, is one of 2 in phase 1, and was the 15th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

1 of the 17 studies in Uterine Cervical Neoplasms by Memorial Sloan Kettering Cancer Center is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Uterine Cervical Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to see if a radioactive substance called 18F-Fluorodeoxyglucose (18F- FDG), injected into the cervix during a PET/CT scan done before surgery can show us more clearly which lymph nodes in the pelvis (the area near your uterus and cervix) contain cancer.

03

Conditions studied

  • Cervical Cancer
  • Endometrial Cancer

Keywords

  • 18F-FDG Injection
  • Positron Lymphography
  • Lymphatic Mapping
  • sentinel lymph nodes
  • PET/CT
  • 14-222
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study population will include women with stage IB1 cervical cancer (any histologic subtype) deemed eligible for surgery, and women with a clinical stage I high-grade endometrial cancer planning to undergo surgical staging. High grade is defined by the following:

    • Uterine serous carcinoma
    • Clear cell endometrial carcinoma
    • Grade 3 endometrioid carcinoma
    • Endometrial carcinosarcoma
    • Clinical stage I grade 1-2 endometrial cancer also eligible with deep myoinvasion ≥ 50% shown on preop MRI and/or elevated preop CA-125 > 35 U/ml.
  • Age ≥18 years
  • ≥10 g/dL
  • Plasma albumin ≥3 g/dL
  • GOG performance status ≤2
  • Plasma glucose ≤200 mg/dL
  • Plasma creatinine ≤1.6
  • Well-controlled hypertension
  • Medical clearance for surgery and considered an appropriate surgical candidate
  • Negative serum pregnancy test, if of
  • If, based on surgeon's assessment, the patient is recommended to undergo surgical staging for confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease
  • Participation in other research protocols does not exclude a patient from participation in this study

Exclusion criteria

Exclusion Criteria:

  • \<10 g/dL
  • Plasma albumin \<3 g/dL
  • GOG performance status >2
  • Plasma glucose >200 mg/dL
  • Renal insufficiency with plasma creatinine >1.6
  • Uncontrolled hypertension
  • Patient does not meet medical clearance for surgery and is not considered an appropriate surgical candidate
  • Pregnancy

For Stage 2:

  • Patient who are unwilling or unable to undergo MRI including patients with to MRI such as the presence of cardiac pacemakers of non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.
  • Patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of MRI
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    intracervical 18F-FDG injection during a dynamic PET/CT

    The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.

    Radiation: 18F-Fluorodeoxyglucose (18F-FDG) · Device: PET/CT imaging · Device: PET/MRI imaging

Interventions

  • Radiation18F-Fluorodeoxyglucose (18F-FDG)
  • DevicePET/CT imaging
  • DevicePET/MRI imaging
06

What researchers measure

Primary outcomes

  1. diagnostic accuracy of Positron Lymphography

    Accuracy of Positron Lymphography will be defined in terms of sensitivity and will consist of pathology review of labelled, excised specimens compared with lymph node imaging data acquired preoperatively.

    Time frame: 2 years

Secondary outcomes

  1. to evaluate several standard uptake value (SUV) (18F-FDG avidity)

    will assess the ability of SUV to predict malignant disease. The continuous variable of SUV assigned to a given lymph node during Positron Lymphography will be compared with the pathologic assessment (benign vs malignant) of each labelled lymph node. The SUV assigned to a given lymph node is done using the the imaging software and not up to the discretion of the radiologist.

    Time frame: 2 years

07

Study locations

7 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2014 (actual). Primary completion is estimated for Nov 2026, 144 months after the start.

Of 59 non-industry phase 1 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 72. This study's planned 144 months is above that.

Counting every sponsor, half of 143 studies reached it within 47 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2014
First posted
Nov 6, 2014
StartActual
Nov 2014
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02285192
Responsible party
Sponsor
First posted
Nov 6, 2014
Start date
Nov 2014
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Jennifer Mueller, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion